Generic Medicines Conference Europe 2007, Berlin

Posted by Generic Medicines Europe

The Generic Medicines Europe 2007 conference is to be held in the Radisson SAS Hotel, Berlin, Germany on 25-27 September 2007.  The conference will examines the key issues, outages and strategies for success in the generics and biosimilars markets

Driving generics and biosimilars business strategies to the next level

• More hours of dedicated networking than any other generics event
• Troubleshoot challenges in regulation, litigation and accessing API
• Optimise your companies manufacturing and compliance capabilities
• Stay competitive; understand how business models are continually evolving in this sector
• The best mix of industry speakers from the pharmaceutical, generics, biotech, legal and non-for-profit sectors

Meet one of Fortune Magazines ‘Top 24 Innovators’

The May edition of Fortune magazine featured a special article entitled ‘Innovators at the gate’. This focused on the work of 24 individuals who are doing their best to create new industries against all the odds. Sunil Shaunak is Professor of Infectious Diseases at Imperial College and Hammersmith Hospital London and a co-founder of PolyTherics. Professor Shaunak is dedicated to making patented cost-affordable medicines for patients who currently receive no treatment. The key underlying concept is manufacturing a compound that is similar to a patented medicine with proven and important clinical benefit, but different enough to avoid issues with patents and IP. This is known as ‘ethical pharmaceuticals’.

Professor Shaunak is an entrepreneur with a zeal for creativity and thinking outside the box. His key note address at Generic Medicines Europe 2007 promises to be both thought-provoking and an opportunity to look at new pharmaceutical horizons in the 21st Century. This will be an unmissable talk on ‘ethical pharmaceuticals’ and their potential to become a new driver for the pharmaceutical industry. Professor Shaunak and his colleague, Steve Brocchini from the London School of Pharmacy, already have a hepatitis C drug in clinical trials and have started work on a drug for leishmaniasis with funding from the Drugs for Neglected Diseases Initiative and the National Institutes of Health (USA).

Unmissable key addresses on the role of generics in the developing world

Alongside this talk, we have key addresses from several other internationally recognised leaders who are also dedicated to addressing key developing world disease treatment issues via strategic collaborations, IP, the provision of cost-affordable medicines and generics. Speakers include Dr Anthony So from Duke University, Precious Matsoso from the WHO and Dr Katherine Woo from the Institute for OneWorld Health. Generics have a central role to play in reducing the cost of healthcare in developing countries. These sessions will focus on the latest thinking, strategies, policies and government guidelines.

Generic Medicines Europe 2007 examines the key issues, outages and strategies for success in the generics and biosimilars markets. This is an unrivalled forum for discussing the latest updates in business model adaptation across the pharmaceutical industry, regulatory guidelines, manufacturing best practice, growth markets, pharmaceutical litigation and IP and accessing API. This is the definitive conference for leaders in the generics, biosimilars and non-profit sectors to meet, exchange ideas and network.

The generics industry is booming. According to reports, the global generics market is worth over $45bn and this is growing year on year. The loss of patent protection for a number of lucrative drugs by 2010 will continue to drive this exceptional market growth. The biosimilars market also looks set to be a key future driver of the biopharmaceutical industry. Europe has already seen the first regulatory approvals of biosimilar drugs and there is increasing government pressure to repeat this in the USA.

As competition in this sector continually increases and pricing pressure intensifies, companies must optimise their business strategies in order to remain competitive.

Traditional pharmaceutical companies are also adapting their business models in response to the generics boom, particularly through the use of ‘authorised generics’.

Therefore in order to maintain growth and profitability, generics companies must have excellent competitive intelligence, an understanding of strategic partnering and M&A, access to API and a continual understanding of updates in pharmaceutical legislation and regulation.

The biosimilars sector is also facing a number of challenges which are restricting market expansion. The release of regulatory guidelines for biosimilars in the USA has been delayed indefinitely and a greater understanding of biosimilar approval in Europe is needed before companies can really begin to move forward in this area.

There are also a number of manufacturing complexities which need to be addressed. Generic Medicines Europe 2007 examines the key issues, outages and strategies for success in the generics and biosimilars markets. This is an unrivalled forum for discussing the latest updates in business model adaptation across the generics industry, regulatory guidelines, manufacturing best practice, growth markets, pharmaceutical litigation and IP and accessing API.
Who should attend?

If you fall into one of the industry categories below then Generic Medicines Europe 2007 is a must attend event for you. This meeting will show you how to troubleshoot the key industry issues and put you at the forefront of this dynamic market.

• Generics Pharmaceutical Manufacturers
• Traditional Pharmaceutical Manufacturers
• Biotechs
• Contract Manufacturing Organisations
• Contract Research Organisations
• Research Institutes
• Government and Regulatory Bodies
• Legal Practices
• Consultants